0000000000217004

AUTHOR

Nicholas C. Harvey

showing 4 related works from this author

Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects o…

2022

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds…

AgingBone Density Conservation Agents610 Medicine & healthVitaminsFragility fractureVitamin D DeficiencyFractures BoneFalls Fragility fracture Osteoarthritis Vitamin DDietary SupplementsOsteoarthritisHumansOsteoporosisFallsGeriatrics and GerontologyVitamin D610 Medicine & healthAgedCalcifediolAging clinical and experimental research
researchProduct

Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium

2014

Quantitative ultrasound of the heel captures heel bone properties that independently predict fracture risk and, with bone mineral density (BMD) assessed by X-ray (DXA), may be convenient alternatives for evaluating osteoporosis and fracture risk. We performed a meta-analysis of genome-wide association (GWA) studies to assess the genetic determinants of heel broadband ultrasound attenuation (BUA; n = 14 260), velocity of sound (VOS; n = 15 514) and BMD (n = 4566) in 13 discovery cohorts. Independent replication involved seven cohorts with GWA data (in silico n = 11 452) and new genotyping in 15 cohorts (de novo n = 24 902). In combined random effects, meta-analysis of the discovery and repli…

MaleOncologyHeelBone densityOsteoporosisGenome-wide association studyCohort StudiesFractures Bonequantitative ultrasoundBone DensityGenetics (clinical)riskUltrasonographyAged 80 and overGeneticsmedicine.diagnostic_testAssociation Studies Articlesphenotypesta3141General MedicineMiddle Aged3. Good healthmedicine.anatomical_structureosteoporosis diagnostic radiologic examination roentgen rays ultrasonography bone mineral density fractures calcaneus chromosomes genes genome heel longevity single nucleotide polymorphism sound genetics chromosome 7q31 genotype determination genome-wide association study attenuation osteoporotic fracture risk/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalewomenAdultmusculoskeletal diseasesmedicine.medical_specialtyx-ray absorptiometrySingle-nucleotide polymorphismdensitometryBiologyPolymorphism Single NucleotidecalcaneusYoung AdultSDG 3 - Good Health and Well-beingInternal medicineGeneticsmedicineHumansGenetic Predisposition to DiseaseMolecular BiologyDual-energy X-ray absorptiometryVLAGAgedGlobal NutritionWereldvoedingta1184ta3121medicine.diseaseosteoporosisCalcaneusGenetic epidemiologyfractureOsteoporosismineral densityCalcaneusGenome-Wide Association Study
researchProduct

Novel formulations of oral bisphosphonates in the treatment of osteoporosis

2022

AbstractOral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel oral bisphosphonate formulations. Buffered, effervescent alendronate is dissolved in water and so seeks to reduce upper gastro-intestinal adverse events, and gastro-resistant risedronate aims to reduce the complexity of dosing procedure (e.g. fasting prior to consumption) whilst still mainta…

AgingDiphosphonatesAlendronateAlendronate/adverse effects610 Medicine & healthRisedronic Acid/therapeutic useDiphosphonates/adverse effectsFractures BoneHumansOsteoporosisAlendronate Bisphosphonates Fragility fracture Osteoporosis Risedronate TherapyGeriatrics and Gerontology610 Medizin und GesundheitBoneFracturesRisedronic AcidOsteoporosis/drug therapy
researchProduct

Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures

2019

Summary Guidance is provided in an international setting on the assessment and specific treatment of postmenopausal women at low, high and very high risk of fragility fractures. Introduction The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2019. This manuscript seeks to apply this in an international setting, taking additional account of further categorisation of increased risk of fracture, which may inform choice of therapeutic approach. Methods Clinical perspective and updated literature search. Results The following areas are reviewed: …

0301 basic medicinemedicine.medical_specialtyFRAXEndocrinology Diabetes and MetabolismeducationOsteoporosisPsychological interventioninhibitors of bone resorption030209 endocrinology & metabolismRisk AssessmentAnabolic agents03 medical and health sciencesTherapeutic approach0302 clinical medicineBone DensityRisk FactorsTreatment of osteoporosisInternal medicinemedicinefracture risk assessmentHumansanabolic agentsIntensive care medicineOsteoporosis PostmenopausalAgedAnabolic agents Fracture risk assessment FRAX Inhibitors of bone resorption Treatment of osteoporosisddc:616Postmenopausal womenbusiness.industryCorrectionFracture risk assessmentInhibitors of bone resorptionMiddle Agedtreatment of osteoporosismedicine.diseaseRheumatologyIncreased riskFemalePosition Paper030101 anatomy & morphologybusinessVery high riskAlgorithmsOsteoporotic FracturesFRAXOsteoporosis International
researchProduct